109 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd.
14 Jun 24
Report of Foreign Private Issuer
7:26am
MARKETS WITH UNDERSERVED NEEDS Common diseases (e.g. COVID - 19, Influenza) Platform potential for response to emerging pandemic pathogens Atopic
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd.
25 Apr 24
Report of Foreign Private Issuer
4:00pm
ADDRESSING LARGE MARKETS WITH UNDERSERVED NEEDS Common diseases (e.g. COVID - 19, Influenza) Platform potential for response to emerging pandemic pathogens
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd.
18 Jan 24
Report of Foreign Private Issuer
11:50am
- 19, Influenza) Platform potential for response to emerging pandemic pathogens Atopic Dermatitis $9.2B Source: GlobalData, 7 major markets (US, 5EU
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd.
9 Jan 24
Report of Foreign Private Issuer
8:45am
- 19, Influenza) Platform potential for response to emerging pandemic pathogens Atopic Dermatitis $9.2B Source: GlobalData, 7 major markets (US, 5EU
10-K
cjuplrkexozs
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
xku9 zv4o6
29 Dec 22
Report of Foreign Private Issuer
10:39am
6-K
EX-99.1
g4vfy264zme
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
424B4
mcmoi mavcepb50x
20 Dec 22
Prospectus supplement with pricing info
11:59am
6-K
EX-99.1
shwycu706hijqorha
19 Dec 22
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
6:02am
6-K
EX-99.1
l23umscginfahe1zwuy
14 Dec 22
Report of Foreign Private Issuer
9:11am
F-1/A
vfvofg 5bj39h7p613p
12 Dec 22
Registration statement (foreign) (amended)
5:25pm
6-K
EX-99.1
whgtsxik
30 Nov 22
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
2:41pm
6-K
EX-99.1
1qyi1o
29 Nov 22
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
11:09am
6-K
EX-99.1
qsaghuunct
8 Nov 22
1 RAFT meeting | 6 - 9 NOVEMBER 2022 Dalit Weinstein - Fischer
4:53pm
6-K
EX-99.1
2l8e9t2mnzd8s1rdv
3 Oct 22
BiondVax announces financial plans to support its ongoing NanoAb pipeline development
4:05pm
F-1
ln7fluljyr
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-99.1
plxfu62x6 of4q3
21 Sep 22
Report of Foreign Private Issuer
6:04am
6-K/A
EX-99.1
8k210utcj
29 Aug 22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
4:51pm
6-K
EX-99.1
t429cnzo90egl5u9iik
25 Aug 22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
4:02pm